MK-677, also called ibutamoren, is an oral compound that mimics ghrelin, the hormone that tells the brain to release growth hormone and to eat. It is not a steroid and not a SARM, and it has never been approved as a medicine.
It is popular because it is swallowed rather than injected and because it raises growth hormone and IGF-1 measurable on blood work. This guide covers what the receptor does, what trials measured, what goes wrong, and which numbers are worth tracking.
Key facts about MK-677
| Chemical name | Ibutamoren, also written MK-677 |
| Class | Oral growth hormone secretagogue, ghrelin receptor agonist |
| Molecular formula | C27H36N4O5S, molecular weight 528.7 |
| Route | Oral, usually as capsules or liquid |
| Approved status | Not approved as a medicine anywhere |
| Main measurable effect | Rise in growth hormone and IGF-1, plus appetite |
| Main practical concerns | Appetite, water retention, glucose, and no long term safety data |
IGF-1 is the readout that moves first. Body composition moves later, less and with more individual variation.
What MK-677 is
Ibutamoren belongs to a class called growth hormone secretagogues. These compounds were developed in the 1990s, before ghrelin itself was discovered, by looking for small molecules that would make the pituitary release growth hormone. When ghrelin was identified as the natural ligand for the same receptor, the class got its explanation: these drugs imitate a hunger signal.
Three distinctions are worth keeping straight, because forum posts blur them constantly:
- Not a steroid. It does not bind the androgen receptor and does not build muscle through that route.
- Not a SARM. It is not selective for androgen tissue and has nothing to do with that family of drugs.
- Not growth hormone. It does not add hormone from outside. It asks your pituitary to release more of its own, in pulses.
How it raises growth hormone
MK-677 binds the growth hormone secretagogue receptor, the same receptor ghrelin uses, in the pituitary and the hypothalamus. Activation increases the size of growth hormone pulses rather than producing a constant level, which is the physiological difference between this class and injected growth hormone.
A 2023 review of growth hormone secretagogues describes the feedback that limits the effect: IGF-1 rises in response to growth hormone, and IGF-1 itself feeds back to restrain further release. That is why these compounds are described as restoring a rhythm rather than pushing a constant flood. In older adults the review reports that growth hormone output can be restored toward levels seen in people in their twenties, with an increase in fat free mass and a redistribution of fat toward the limbs.
The same receptor explains the appetite: ghrelin is the hunger signal, so hunger is the mechanism working, not a side effect.
What the trials measured
Most of the clinical research on ibutamoren comes from small studies in older adults and in specific conditions, not from performance research. What the literature supports:
| Endpoint | What was reported | How strong the evidence is |
|---|---|---|
| Growth hormone and IGF-1 | Clear, dose related increases in both | Consistent across studies, this is the reliable part |
| Fat free mass | Increase reported in older adults | Small studies, short duration |
| Fat distribution | Shift of fat toward the limbs described in the review | Small studies, modest effect |
| Strength and performance | Not established | No reliable data in trained populations |
| Appetite | Increase, consistent with the ghrelin mechanism | Reported by users and consistent with pharmacology |
The honest summary: this compound does what it says on the hormone panel, and the body composition changes are smaller and less certain than the marketing suggests.
Appetite, weight and water
Because the target receptor is the ghrelin receptor, hunger is not a side effect in the accidental sense. It is part of the drug's action. A 2025 review of ghrelin biology describes the receptor as a regulator that goes well beyond hunger, involved in reward, glucose handling and whole body energy balance, which is also why the effects of stimulating it are broader than appetite alone.
In practice people report two things in the first weeks: eating more, and looking fuller. The second is partly water. Stimulating growth hormone and increasing food intake both tend to increase extracellular fluid, which is why ankles, hands and the face can look puffy. It usually settles, and it is not muscle.
What is not known
| Question | State of the evidence |
|---|---|
| Long term safety beyond a year | Not established, no large trials |
| Effect on glucose and insulin sensitivity with prolonged use | Unclear, and this is the main theoretical concern with growth hormone elevation |
| Effect on pituitary function after stopping | Poorly described |
| Interaction with other compounds | Almost no data |
| Quality of products sold online | Variable, and unapproved status means no pharmacist check |
Growth hormone and glucose are linked: growth hormone opposes insulin. Anyone raising growth hormone for months should be watching fasting glucose and HbA1c rather than assuming it is harmless because it is not a steroid.
A case worth reading
A 2024 case report describes a 40 year old man who developed bilateral gynecomastia and hypogonadotropic hypogonadism after six months of taking commercially sold performance supplements for the gym. Analysis found the products contained RAD-140, MK-677 and cardarine, along with undeclared testosterone, estradiol and growth hormone.
The point of the case is not that MK-677 caused gynecomastia on its own. The point is that the man did not know what he was taking, and neither would anyone reading a label that did not list those compounds. Whatever compound you choose, knowing exactly what is in the product is the first safety measure, and it comes before dose, timing and everything else.
Dose, forms and what people actually run
There is no approved dose, so what follows describes common practice, not a recommendation. It is usually sold next to SARMs rather than steroids, so the SARM category is where to compare what is available.
| Item | Common practice | Reality check |
|---|---|---|
| Form | Capsules or liquid, taken by mouth | Liquid products make accurate dosing harder than capsules |
| Daily amount | Usually 10 to 25 mg | No validated male dose exists, and effects on IGF-1 are dose related |
| Timing | Evening, before sleep | Growth hormone is released mostly during sleep, but timing has not been compared in trials |
| Duration | 8 to 12 weeks, sometimes longer | No long term safety data beyond that window |
| Cycle support | Often stacked with SARMs | Stacking multiplies unknowns, not just effects |
Two practical points follow from the pharmacology. First, because the effect is mediated by your own pituitary, a bigger dose does not produce a proportional result once IGF-1 feedback kicks in. Second, because appetite rises, the dose has a direct effect on how much you eat, which changes body composition independently of growth hormone.
MK-677 compared with injected growth hormone
These are different tools and they are marketed as if they were the same thing.
| MK-677 | Injected growth hormone | |
|---|---|---|
| How it works | Stimulates your own pulses through the ghrelin receptor | Adds exogenous hormone directly |
| Route | Oral | Subcutaneous injection |
| Control | Limited by IGF-1 feedback | Dose determines the level, with no feedback ceiling |
| Monitoring | IGF-1, glucose | IGF-1, glucose, and medical supervision in approved use |
| Approved status | Not approved | Approved for specific indications under a doctor |
Growth hormone itself is a prescription medicine with defined indications, and its misuse carries well described risks including fluid retention, joint pain, carpal tunnel symptoms and effects on glucose. A secretagogue is not a safer version of the same thing: it is a different mechanism with its own unknowns.
Blood work and monitoring
| Marker | Why it matters | When |
|---|---|---|
| IGF-1 | The most direct readout of growth hormone activity | Baseline, week 4, then every 8 to 12 weeks |
| Fasting glucose and HbA1c | Growth hormone opposes insulin | Baseline and every 3 months |
| Blood pressure and weight | Water retention shows up here first | Weekly |
| Total and free testosterone, LH, FSH | To see whether the axis is affected, especially with stacked products | Baseline and after 8 weeks |
| Prolactin | Relevant if libido or breast symptoms appear | If symptoms appear |
Example structure, not a recommendation
The table below is a common shape for a run of this kind, written out so the timing and the checkpoints are visible. It is not advice, not a protocol to copy, and not a substitute for a doctor who has seen your blood work.
| Stage | What people typically do | What to check |
|---|---|---|
| Week 1 | 10 mg in the evening | Baseline IGF-1, fasting glucose |
| Weeks 2 to 8 | 10 to 25 mg, depending on tolerance | Watch appetite, sleep, ankle swelling |
| Week 8 | IGF-1 and glucose recheck | Decide on continuation from numbers |
| After | Stop and reassess in 4 weeks | IGF-1 returns toward baseline |
Frequently Asked Questions
Where this fits on this site
Ibutamoren is usually sold next to SARMs rather than steroids, and our SARM category is where to compare what is available. For the recovery side of any cycle, start with post cycle therapy. If you are weighing growth hormone pathways against androgen pathways, the Anavar guide shows the androgen route, and the Ostarine article covers the receptor that MK-677 is often confused with.
- PubChem compound summary for ibutamoren, CID 178024: molecular formula C27H36N4O5S, molecular weight 528.7
- Growth hormone secretagogues as potential therapeutic agents to restore growth hormone secretion, 2023. PMID 37325967
- Beyond hunger: the structure, signaling, and systemic roles of ghrelin, 2025. PMID 41303478
- Reversible gynecomastia and hypogonadism due to usage of commercial performance-enhancing supplement use, 2024. PMID 39145153
Medical disclaimer. This article is informational and does not replace advice from a licensed physician. Ibutamoren is unapproved, long term safety data is thin, and raising growth hormone has measurable effects on glucose and fluid balance.